Method for producing powder formulation comprising an insulin
First Claim
Patent Images
1. A therapeutic powder formulation suitable for pulmonary administration, comprising particles which comprise (i) human insulin, any analogue or derivative thereof, or combinations of the foregoing;
- and (ii) an enhancer which enhances the absorption of insulin in the lower respiratory tract, wherein at least 50% by weight of said particles are crystalline and wherein the molar ratio of insulin to enhancer is between about 9;
1 and 1;
9.
1 Assignment
0 Petitions
Accused Products
Abstract
A therapeutic powder formulation suitable for pulmonary administration comprising particles composed of human insulin or any analogue or derivative thereof and an enhancer which enhances the absorption of insulin in the lower respiratory tract, wherein at least 50% by weight of the particles are crystalline.
223 Citations
20 Claims
-
1. A therapeutic powder formulation suitable for pulmonary administration, comprising particles which comprise (i) human insulin, any analogue or derivative thereof, or combinations of the foregoing;
- and (ii) an enhancer which enhances the absorption of insulin in the lower respiratory tract, wherein at least 50% by weight of said particles are crystalline and wherein the molar ratio of insulin to enhancer is between about 9;
1 and 1;
9. - View Dependent Claims (2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15)
- and (ii) an enhancer which enhances the absorption of insulin in the lower respiratory tract, wherein at least 50% by weight of said particles are crystalline and wherein the molar ratio of insulin to enhancer is between about 9;
-
16. A therapeutic powder formulation suitable for pulmonary administration, comprising co-crystals of (i) human insulin, any analogue or derivative thereof, or combinations of the foregoing;
- and (ii) an enhancer which enhances the absorption of insulin in the lower respiratory tract, wherein the molar ratio of insulin to enhancer in said crystals is between about 9;
1 and 1;
9.
- and (ii) an enhancer which enhances the absorption of insulin in the lower respiratory tract, wherein the molar ratio of insulin to enhancer in said crystals is between about 9;
-
17. A therapeutic powder formulation suitable for pulmonary administration comprising particles composed of (i) human insulin, any analogue or derivative thereof, or combinations of the foregoing;
- and (ii) an enhancer which enhances the absorption of insulin in the lower respiratory tract, wherein at least 50% of said particles are crystalline and wherein said enhancer is sodium taurocholate.
-
18. A therapeutic powder formulation suitable for pulmonary administration comprising particles composed of (i) human insulin, any analogue or derivative thereof, or combinations of the foregoing;
- (ii) an enhancer which enhances the absorption of insulin in the lower respiratory tract, and (iii) a stabilizing amount of a phenolic compound wherein at least 50% of said particles are crystalline.
- View Dependent Claims (19, 20)
Specification